Kronos Bio (KRON) Competitors

Kronos Bio (NASDAQ:KRON) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.

Which has more volatility and risk, KRON or NLTX?

Kronos Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in KRON or NLTX?

64.1% of Kronos Bio shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 24.4% of Kronos Bio shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings & valuation, KRON or NLTX?

Neoleukin Therapeutics has lower revenue, but higher earnings than Kronos Bio. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kronos Bio	$9.19M	5.79	-$112.67M	-$1.07	-0.82
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	-6.94

Does the media prefer KRON or NLTX?

In the previous week, Kronos Bio had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 8 mentions for Kronos Bio and 1 mentions for Neoleukin Therapeutics. Kronos Bio's average media sentiment score of 0.83 beat Neoleukin Therapeutics' score of 0.00 indicating that Kronos Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kronos Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neoleukin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate KRON or NLTX?

Kronos Bio presently has a consensus price target of $1.63, suggesting a potential upside of 86.31%. Given Kronos Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kronos Bio is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kronos Bio	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community prefer KRON or NLTX?

Neoleukin Therapeutics received 29 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 65.63% of users gave Kronos Bio an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

Company	Underperform	Outperform
Kronos Bio	Outperform Votes 21 65.63%	Underperform Votes 11 34.38%
Neoleukin Therapeutics	Outperform Votes 50 45.87%	Underperform Votes 59 54.13%

Is KRON or NLTX more profitable?

Neoleukin Therapeutics has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Neoleukin Therapeutics' return on equity of -37.22% beat Kronos Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kronos Bio	-867.66%	-64.55%	-48.18%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Kronos Bio beats Neoleukin Therapeutics on 12 of the 17 factors compared between the two stocks.